Pancreatic cancer
Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10%
in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk …
in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk …
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
AJ Grossberg, LC Chu, CR Deig… - CA: a cancer journal …, 2020 - Wiley Online Library
Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …
the prognosis for this disease remains very poor, largely because of delayed disease …
[HTML][HTML] The immune microenvironment in pancreatic cancer
M Huber, CU Brehm, TM Gress, M Buchholz… - International journal of …, 2020 - mdpi.com
The biology of solid tumors is strongly determined by the interactions of cancer cells with
their surrounding microenvironment. In this regard, pancreatic cancer (pancreatic ductal …
their surrounding microenvironment. In this regard, pancreatic cancer (pancreatic ductal …
Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus gemcitabine/nab-paclitaxel for perioperative treatment of resectable …
SA Ahmad, M Duong, DPS Sohal, NS Gandhi… - Annals of …, 2020 - journals.lww.com
Objective: The optimal neoadjuvant therapy for resectable pancreatic ductal
adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. Methods …
adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. Methods …
Evaluation of adjuvant chemotherapy in patients with resected pancreatic cancer after neoadjuvant FOLFIRINOX treatment
S van Roessel, E van Veldhuisen… - JAMA …, 2020 - jamanetwork.com
Importance The benefit of adjuvant chemotherapy after resection of pancreatic cancer
following neoadjuvant combination treatment with folinic acid, fluorouracil, irinotecan, and …
following neoadjuvant combination treatment with folinic acid, fluorouracil, irinotecan, and …
[HTML][HTML] Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomized controlled trials
The efficacy of neoadjuvant therapy (NT) versus surgery first (SF) for pancreatic ductal
adenocarcinoma (PDAC) remains controversial. A random-effects meta-analysis of only …
adenocarcinoma (PDAC) remains controversial. A random-effects meta-analysis of only …
[HTML][HTML] Pancreatic cancer treatment: better, but a long way to go
Remarkable progress has been made in treating pancreatic cancer over the past century,
including refinement of our surgical techniques and improvements in adjuvant and …
including refinement of our surgical techniques and improvements in adjuvant and …
Prehabilitation prior to surgery for pancreatic cancer: a systematic review
JR Bundred, SK Kamarajah, JS Hammond, CH Wilson… - Pancreatology, 2020 - Elsevier
Introduction Prehabilitation aims to improve fitness and outcomes of patients undergoing
major surgery. This systematic review aimed to appraise current available evidence …
major surgery. This systematic review aimed to appraise current available evidence …
Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19
Abstract As of April 6, 2020, there are over 1,200,000 reported cases and 70,000 deaths
worldwide due to COVID-19, the disease caused by the SARS-CoV-2 virus, and these …
worldwide due to COVID-19, the disease caused by the SARS-CoV-2 virus, and these …
Single-nucleus and spatial transcriptomics of archival pancreatic cancer reveals multi-compartment reprogramming after neoadjuvant treatment
Pancreatic ductal adenocarcinoma (PDAC) remains a treatment-refractory disease.
Characterizing PDAC by mRNA profiling remains particularly challenging. Previously …
Characterizing PDAC by mRNA profiling remains particularly challenging. Previously …